REVEAL Trial

High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
REVEAL Trial On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of REVEAL Trial All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on REVEAL Trial
CDC on REVEAL Trial
REVEAL Trial in the news
Blogs on REVEAL Trial
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for REVEAL Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Timeline

Start Date: June 2011
Expected End Date: January 2017

Objective

The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) is prospective, randomized, multicenter, placebo-controlled, double-blind clinical trial that will enroll 30,000 patients with high low density lipoprotein (LDL) receiving HMG-CoA reductase inhibitor (statin) therapy.

The study will evaluate the therapeutic effect of anacetrapib 100 mg on lipid profile alteration and role in reduction of cardiovascular morbidity and mortality in patients with baseline circulatory problems.